Research Progress of MicroRNA Related to Chemotherapy Resistance in Head and Neck Cancer

doi:10.13701/j.cnki.kqyxyj.2018.06.005

Abstract

Abstract: Head and Neck Cancer (HNC) is one of the most common malignancies in the world. At present, cisplatin based chemotherapy and adjuvant radiotherapy is still the first-line treatment for advanced patients. However, the treatment effect of patients is often limited by the tolerance of cancer cells to chemotherapy drugs, which ultimately leads to treatment failure and death. In recent years, miRNAs has been found to play an important role in tumor progression, metastasis, invasion, and drug resistance. Through literature review, we found that the expression of miRNAs can lead to head and neck cancer resistance through a variety of ways, including the mechanisms of multidrug resistance (MDR) transporters, anti-apoptosis, DNA damage repair, epithelial mesenchymal transition (EMT), cancer stem cells (CSCs), drug target change, and metabolism. This article reviews and explores the use of miRNAs adjuvant chemotherapy strategy.

Key words: MicroRNA, Drug resistance, Head and neck cancer

YIN Xi-teng,HAN Wei. Research Progress of MicroRNA Related to Chemotherapy Resistance in Head and Neck Cancer[J]. Journal of Oral Science Research, 2018, 34(6): 594-596.

References

[1] Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world [J]. J Clin Oncol, 2006, 24(14):2137-2150
[2] Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014 [J]. Ca Cancer J Clin, 2014, 64(1):9-29
[3] Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review [J]. EMBO Mol Med, 2012, 4(3):143-159
[4] Ghosh RD, Ghuwalewala S, Das P, et al. MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features [J]. Sci Rep, 2016, 6:23932
[5] Dai Y, Xie CH, Neis JP, et al. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance [J]. Head Neck, 2011, 33(6):786-791
[6] Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm [J]. Nat Rev Cancer, 2013, 13(10):714-726
[7] Lu S, Yu L, Mu Y, et al. Role and mechanism of Twist1 in modulating the chemosensitivity of FaDu cells [J]. Mol Med Rep, 2014, 10(1):53-60
[8] Yu J, Xie F, Bao X, et al. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer [J]. Mol Cancer, 2014, 13:121
[9] Peng F, Zhang H, Du Y, et al. miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through Twist [J]. Oncol Rep, 2015, 33(2):942-950
[10] Zhao L, Ren Y, Tang H, et al. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential [J]. Oncotarget, 2015, 6(42):44538-44550
[11] Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future [J]. Annu Rev Pharmacol Toxicol, 2014, 54:95-117
[12] Gao M, Miao L, Liu M, et al. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1 [J]. Oncotarget ,2016,7(37):59714-59726
[13] Wang W, Songlin P, Sun Y, et al. miR-21 inhibitor sensitizes human OSCC cells to cisplatin [J]. Mol Biol Rep, 2012,39(5):5481-5485
[14] Ren W, Wang X, Gao L,et al. MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4 [J]. Mol Cell Biochem, 2014,390(1-2):253-262
[15] Suen DF, Norris KL, Youle RJ.Mitochondrial dynamics and apoptosis [J]. Genes Dev, 2008, 22(12):1577-1590
[16] Fan S, Chen WX, Lv XB, et al. miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1 [J]. Cancer Lett, 2015,362 (2):183-191
[17] Fan S, Liu B, Sun L, et al. Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis [J]. Oncotarget,2015,6(17):14885-14904
[18] Wang Z, Li Y, Ahmad A, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance [J]. Drug Resist Updat, 2010, 13(4-5):109-118
[19] Wu B, Lei D, Wang L, et al. MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1 [J]. Am J Cancer Res,2016,6(6):1396-1407
[20] Lo WL, Yu CC, Chiou GY, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells [J]. J Pathol ,2011, 223(4):482-495
[21] Xia H, Cheung WK, Sze J, et al. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling [J]. J Biol Chem, 2010, 285(47):36995-37004
[22] Yu CC, Chen YW, Chiou GY, et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation [J]. Oral Oncol, 2011, 47(3):202-210
[23] Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer [J]. J Clin Oncol, 2007, 25(16):2164-2170
[24] Lin C, Lu W, Ren Z, et al. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma [J]. Cancer Lett, 2016, 377(1):1-10
[25] Sui C, Xu F, Shen W, et al. Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET [J]. Tumour Biol, 2015, 36(3):1511-1518
[26] Tian H, Gao Z, Li H, et al. DNA damage response--a double-edged sword in cancer prevention and cancer therapy [J]. Cancer Lett, 2015, 358(1):8-16
[27] Li X, Li Y, Qiu LH, et al. Expression of excision repair cross-complementation gene in drug-resistant process of carboplatin administration in tongue squamous cell cancer (Tca8113) [J]. Chin J Stomatol, 2011,46(7):437-441